Is this it?, page-7

I don't know, siren. At the moment, the share price reflects both the midkine potential and the évolis revenue stream. I am not one of those investors who believe we're undervalued. I think given what we know, the fair price is around 2-3 cents. If quarterly revenue keep rising, we could leave the 3 cents region permanently, and we could go to 10 cents but sales need to be consistently good for that.

An announcement regarding the potential of CDY would, in my view, not change a thing. We all know about the potential by now. And big pharma companies have their own departments that look at potential takeover targets. I think JnJ or Thermo F. could be interested. Yet it may be just too early.

If CDY keeps showing results, I can see the share price rise to 10 cents based on revenue, but as long as there is no clinical trial, we're mostly betting on évolis revenues and hoping that CxBladder will to top expectations. In order to make CDY rise tenfold, we'd need revenues of at $10 million+ per quarter, in my view.

I am getting increasingly worried about the huge expectations of some investors. Because their hopes cannot currently be fulfilled. Maybe that's why there is still a lot of selling.

Don't get me wrong. I'm super bullish. The potential is huge. But it needs to happen first, and investors should not inflate their expectations. Midkine is great and could be the holy grail but at this point a treatment is years to go. In my view, we need to see breakeven to see the share price rise. Then we can talk potential. I'm in here for both the growth CDY has shown and the long term potential. And I want to be in early to benefit from a potential takeover. But unless a biggie buys out CDY I don't see a ten bagger here - not yet. Only exploding sales of évolis or a takeover can do that, in my opinion. At least for the moment.